343 results on '"Onali, Sara"'
Search Results
2. Telemedicine in inflammatory bowel disease from its origin to the post pandemic golden age: A narrative review
3. Use of biologics for the management of Crohn's disease: IG-IBD clinical guidelines based on the GRADE methodology
4. Drug-Related Pneumonitis in Patients Receiving Vedolizumab Therapy for Inflammatory Bowel Disease
5. Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology
6. Female reproductive health and inflammatory bowel disease: A practice-based review
7. Adherence to Mediterranean Diet and Diet Quality in Patients with Inflammatory Bowel Disease: A Single-Center, Observational, Case-Control Study
8. Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy
9. A Pharmacological Batch of Mongersen that Downregulates Smad7 is Effective as Induction Therapy in Active Crohn’s Disease: A Phase II, Open-Label Study
10. Response Assessed by Ultrasonography as Target of Biological Treatment for Crohn’s Disease
11. Crohn’s disease and ulcerative colitis patient-reported outcomes signs and symptoms for the remote management of inflammatory bowel disease during the COVID-19 pandemic
12. GPR120/FFAR4: A Potential New Therapeutic Target for Inflammatory Bowel Disease
13. Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)
14. Immune system and gut microbiota senescence in elderly IBD patients.
15. 12 COMPARISON OF TWO STRATEGIES FOR THE MANAGEMENT OF POSTOPERATIVE RECURRENCE IN CROHN'S DISEASE PATIENTS WITH ONE CLINICAL RISK FACTOR: A MULTICENTRE ITALIAN STUDY
16. Post-operative recurrence of Crohn's disease: A prospective study at 5 years
17. Impact of a multidisciplinary approach in enteropathic spondyloarthritis patients
18. Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab
19. SARS-CoV-2 infection in patients with inflammatory bowel disease: comparison between the first and second pandemic waves
20. GPR120/FFAR4: A Potential New Therapeutic Target for Inflammatory Bowel Disease.
21. Use of biologics for the management of Crohn's disease: IG-IBD clinical guidelines based on the GRADE methodology
22. Comparison of two strategies for the management of postoperative recurrence in Crohn’s disease patients with one clinical risk factor: A multicentre IG‐IBD study
23. Metastatic Melanoma: A Rare Cause of Gastrointestinal Intussusception under Nivolumab
24. Comparative Effectiveness Research: A Roadmap to Sail the Seas of IBD Therapies
25. Early post-operative endoscopic recurrence in Crohn's disease patients: Data from an Italian Group for the study of inflammatory bowel disease (IG-IBD) study on a large prospective multicenter cohort
26. Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy
27. Adalimumab in active ulcerative colitis: A “real-life” observational study
28. Accuracy of Small-Intestine Contrast Ultrasonography, Compared With Computed Tomography Enteroclysis, in Characterizing Lesions in Patients With Crohn's Disease
29. TRAF3IP2 gene is associated with cutaneous extraintestinal manifestations in Inflammatory Bowel Disease
30. Corrigendum to “Telemedicine in inflammatory bowel disease from its origin to the post pandemic golden age: A narrative review” [Digestive and Liver Disease, Volume 56, Issue 1, January 2024, Pages 1-6]
31. Development of a numerical index quantitating small bowel damage as detected by ultrasonography in Crohn's disease
32. Fistulizing pattern in Crohn's disease and pancolitis in ulcerative colitis are independent risk factors for cancer: A single-center cohort study
33. Phase I Clinical Trial of Smad7 Knockdown Using Antisense Oligonucleotide in Patients With Active Crohn's Disease
34. Tu1819 REAL-LIFE EFFECTIVENESS AND SAFETY OF TOFACITINIB AND VEDOLIZUMAB AS A SECOND-LINE THERAPY IN ANTI-TNFS EXPERIENCED PATIENTS ULCERATIVE COLITIS: PRELIMINARY RESULTS OF AN IGIBD STUDY (VE2TO-UC)
35. Tu1113 BOWEL URGENCY IN PATIENTS WITH ULCERATIVE COLITIS: PREVALENCE AND ASSOCIATION WITH CLINICAL, ENDOSCOPIC DATA AND DISABILITY
36. Small bowel capsule endoscopy vs conventional techniques in patients with symptoms highly compatible with Crohn's Disease
37. Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology
38. Steroid-free remission and closure of recto-vaginal fistula using adalimumab in a Crohn's disease patient naïve to anti-tumour necrosis factor alpha antibodies
39. The Italian clinical experience with adalimumab in Crohn's disease: Eleven clinical cases
40. Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohnʼs Disease
41. Frequency, Pattern, and Risk Factors of Postoperative Recurrence of Crohn’s Disease After Resection Different from Ileo-Colonic
42. Multiple Orocutaneous Extraintestinal Manifestations in Ulcerative Colitis Patient: Complete Response to Ustekinumab.
43. Measuring disease activity in Crohn’s disease
44. Laparoscopic Versus Open Ileo-Colonic Resection in Crohn’s Disease: Short- and Long-Term Results from a Prospective Longitudinal Study
45. Additional file 1 of Crohn’s disease and ulcerative colitis patient-reported outcomes signs and symptoms for the remote management of inflammatory bowel disease during the COVID-19 pandemic
46. Immune system and gut microbiota senescence in elderly IBD patients
47. An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors.
48. Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients
49. Tumor Infiltrating Regulatory T Cells in Sporadic and Colitis-Associated Colorectal Cancer: The Red Little Riding Hood and the Wolf
50. Impact of COVID‐19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high‐volume Italian inflammatory bowel disease centre
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.